These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 20215481)

  • 1. Alternative dosing schedules and administration updates for ixabepilone.
    Kossoff E
    J Oncol Pharm Pract; 2011 Sep; 17(3):203-8. PubMed ID: 20215481
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimizing ixabepilone treatment schedules in patients with advanced or metastatic breast cancer.
    Egerton N
    Cancer Chemother Pharmacol; 2010 Nov; 66(6):1005-12. PubMed ID: 20886213
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I study of the novel epothilone analog ixabepilone (BMS-247550) in patients with advanced solid tumors and lymphomas.
    Aghajanian C; Burris HA; Jones S; Spriggs DR; Cohen MB; Peck R; Sabbatini P; Hensley ML; Greco FA; Dupont J; O'Connor OA
    J Clin Oncol; 2007 Mar; 25(9):1082-8. PubMed ID: 17261851
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ixabepilone: a novel microtubule inhibitor for the treatment of locally advanced or metastatic breast cancer.
    Steinberg M
    Clin Ther; 2008 Sep; 30(9):1590-617. PubMed ID: 18840366
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Approved agents for metastatic breast cancer.
    Fornier MN
    Semin Oncol; 2011 Jun; 38 Suppl 2():S3-10. PubMed ID: 21600382
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The optimal therapeutic use of ixabepilone in patients with locally advanced or metastatic breast cancer.
    Boehnke Michaud L
    J Oncol Pharm Pract; 2009 Jun; 15(2):95-106. PubMed ID: 19171553
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lapatinib and ixabepilone for the treatment of metastatic breast cancer.
    Halterman PA
    Pharmacotherapy; 2008 Oct; 28(10):1255-66. PubMed ID: 18823221
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ixabepilone: a new antimitotic for the treatment of metastatic breast cancer.
    Bhushan S; Walko CM
    Ann Pharmacother; 2008 Sep; 42(9):1252-61. PubMed ID: 18648018
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical development of ixabepilone and other epothilones in patients with advanced solid tumors.
    Rivera E; Lee J; Davies A
    Oncologist; 2008 Dec; 13(12):1207-23. PubMed ID: 19088324
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ixabepilone (Ixempra) for breast cancer.
    Med Lett Drugs Ther; 2008 Jan; 50(1278):7-8. PubMed ID: 18219261
    [No Abstract]   [Full Text] [Related]  

  • 11. Phase II randomized trial of weekly and every-3-week ixabepilone in metastatic breast cancer patients.
    Smith JW; Vukelja S; Rabe A; Wentworth-Hartung N; Koutrelakos N; Shao SH; Whittaker T; Wang Y; Asmar L; McDowell DO; Mukhopadhyay P; O'Shaughnessy J
    Breast Cancer Res Treat; 2013 Nov; 142(2):381-8. PubMed ID: 24166282
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ixabepilone: clinical role in metastatic breast cancer.
    Denduluri N; Swain S
    Clin Breast Cancer; 2011 Jun; 11(3):139-45. PubMed ID: 21665133
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advances in breast cancer treatment: the emerging role of ixabepilone.
    Frye DK
    Expert Rev Anticancer Ther; 2010 Jan; 10(1):23-32. PubMed ID: 20014882
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epothilones: clinical update and future directions.
    Donovan D; Vahdat LT
    Oncology (Williston Park); 2008 Apr; 22(4):408-16; discussion 416, 421, 424 passim. PubMed ID: 18472615
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ixabepilone, a new treatment option for metastatic breast cancer.
    Toppmeyer DL; Goodin S
    Am J Clin Oncol; 2010 Oct; 33(5):516-21. PubMed ID: 20023567
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ixabepilone: a novel microtubule-stabilizing agent for the treatment of metastatic breast cancer.
    Goodin S
    Am J Health Syst Pharm; 2008 Nov; 65(21):2017-26. PubMed ID: 18945860
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ixabepilone: a novel antineoplastic agent with low susceptibility to multiple tumor resistance mechanisms.
    Vahdat L
    Oncologist; 2008 Mar; 13(3):214-21. PubMed ID: 18378531
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ixabepilone for the treatment of breast cancer.
    Alvarez RH; Valero V; Hortobagyi GN
    Ann Med; 2011; 43(6):477-86. PubMed ID: 21585248
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I dose escalation study of weekly ixabepilone, an epothilone analog, in patients with advanced solid tumors who have failed standard therapy.
    Awada A; Piccart MJ; Jones SF; Peck RA; Gil T; Lebwohl D; Wu CY; Burris HA
    Cancer Chemother Pharmacol; 2009 Feb; 63(3):417-25. PubMed ID: 18446338
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Managing ixabepilone adverse events with dose reduction.
    Valero V
    Clin Breast Cancer; 2013 Feb; 13(1):1-6. PubMed ID: 23098573
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.